|
|
Vaccine Detail
|
MUC1-FSL-1-TT tricomponent vaccine |
| Vaccine Information |
- Vaccine Name: MUC1-FSL-1-TT tricomponent vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: Glycosylated MUC1 peptide HGVTSAPDT(Tn)RPAPGSTAPPA (Li et al., 2019)
- Muc1
gene engineering:
- Type:
- Description:
- Detailed Gene Information: Click Here.
- Immunization Route: Intraperitoneal injection (i.p.)
- Description: A fully synthetic tricomponent cancer vaccine where FSL-1 adjuvant, tetanus toxoid T-helper epitope (QYIKANSKFIGITE), and glycosylated MUC1 peptide (HGVTSAPDT(?-GalNAc)RPAPGSTAPPA) are covalently linked. Designed to overcome MUC1's low immunogenicity through combined TLR2/6 activation and T-cell dependent immune responses. Demonstrated significant tumor burden reduction in B16-MUC1 bearing mice with highest IgG titers among test compounds, mixed Th1/Th2 responses (IgG1, IgG2a, IgG3 isotypes), elevated IL-6 and IL-12 cytokine levels, and strong antisera binding to MCF-7 and B16-MUC1 tumor cells. Key findings showed tricomponent design superior to bicomponent, glycosylation enhanced immunogenicity versus non-glycosylated peptide, and covalent linkage critical (simple mixture showed low efficacy) (Li et al., 2019).
|
| Host Response |
|
|
| References |
Li et al., 2019: Li M, Wang Z, Yan B, Yin X, Zhao Y, Yu F, Meng M, Liu Y, Zhao W. Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy. MedChemComm. 2019; 10(12); 2073-2077. [PubMed: 32133105].
|
|
